Neurolutions, Inc., founded in St. Louis, Missouri, is dedicated to developing innovative brain-computer interface (BCI) technologies aimed at aiding recovery from neurological injuries. Their core mission is to empower individuals with severe disabilities by enabling them to control prosthetics and mobility devices through thought alone. Neurolutions' flagship product, IpsiHand™, is an FDA-cleared BCI technology designed to accelerate motor recovery for stroke patients, allowing them to regain arm movement and improve their quality of life.
Notable figures associated with Neurolutions include leading neuroscientists and engineers who have contributed to the development of their cutting-edge technology. The company has garnered significant attention and investment from the medical and tech communities due to its groundbreaking approach. Key achievements include the FDA clearance of IpsiHand™ and numerous success stories from users who have experienced significant improvements in their motor functions. Neurolutions continues to make a profound impact on the lives of stroke survivors, offering them renewed independence and hope.
